KC startup lands funding to research treatment of rare infant disease
A Kansas City-based pharmaceutical startup landed $3 million in funding to study a treatment for spinal muscular atrophy.
A rare genetic disease, spinal muscular atrophy, leads to weak muscles, trouble breathing and swallowing. Infants diagnosed with SMA type I, the most severe and most common form of the disease, can't lift their heads. Nearly 80 percent don't live to age 2.
"It's terrible," Shift Pharmaceutical s CEO Steve O'Connor told the Kansas City Business Journal. "Basically, these kids…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Elise Reuter Source Type: news